摘要
绝大多数创新药的ICER值都高于阈值,而“一刀切”地提高其医保准入阈值并不利于激励增量价值高的创新药物研发。应当对创新药进行细分并区别施策,对医保基金无法持续承受,但相较于同类药增量价值较高的创新药,可以由医保和患者共同分担药品费用。
The ICER value of the vast majority of innovative drugs is higher than the threshold,and raising the threshold of medical insurance access indiscriminately is not conducive to stimulating the research and development of innovative drugs with high incremental value.Innovative drugs should be subdivided and policies should be differentiated.Some drugs cannot be sustained by medical insurance funds,however,compared with of similar drugs,they have higher incremental value,as a result,medical insurance and patients can share the drug costs.
出处
《中国医疗保险》
2022年第8期53-55,共3页
China Health Insurance
关键词
创新药
阈值
医保准入
支付模式
innovative drugs
threshold
medical insurance access
payment model
